29 Sep 2020 09:46
Holding(s) in Company
Oxford, U.K. 29 September 2020: Sensyne Health plc (LSE: SENS) ("Sensyne" or the "Company"), the UK Clinical AI company, notes that on 5 June 2020, Acacia Research Corporation (Nasdaq: ACTG) announced that it had entered into an agreement with Link Fund Solutions Limited ("LFS") to purchase shares in a number of public and private life sciences companies from the LF Equity Income Fund which was previously managed by Woodford Investment Management Limited.
The agreement was structured to take ownership of portfolio positions in a staged manner. Sensyne Health welcomes Acacia Research as an 11.8% shareholder and the clarity brought to the market with this announcement for the previously anticipated share transfer.
Clifford Press, CEO of Acacia Research, commented:
"We recognise the extraordinary potential of Sensyne's business model as conceived and implemented by Lord Drayson. As governance-oriented investors, we are impressed by the constructive manner in which Sensyne has engaged with us as a major shareholder. We strongly support the continued development of a very talented management team for the next stage of the Company's growth."
TR-1: Standard form for notification of major holdings | ||||||
NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) | ||||||
1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: | Sensyne Health Plc
Schrödinger Building Heatley Road Oxford Science Park Oxford OX4 4GE United Kingdom | |||||
1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate) | ||||||
Non-UK issuer | ||||||
2. Reason for the notification (please mark the appropriate box or boxes with an "X") | ||||||
An acquisition or disposal of voting rights | X | |||||
An acquisition or disposal of financial instruments | ||||||
An event changing the breakdown of voting rights | ||||||
Other (please specify): | ||||||
3. Details of person subject to the notification obligation | ||||||
Name | Acacia Research Corporation | |||||
City and country of registered office (if applicable) | Irvine, California, United States of America | |||||
4. Full name of shareholder(s) (if different from 3) | ||||||
Name | Merton Acquisition HoldCo LLC | |||||
City and country of registered office (if applicable) | Irvine, California, United States of America | |||||
5. Date on which the threshold was crossed or reached: | 28/09/2020 | |||||
6. Date on which issuer notified (DD/MM/YYYY): | 28/09/2020 | |||||
7. Total positions of person(s) subject to the notification obligation: | ||||||
% of voting rights attached to shares (total of 8.A) | % of voting rights through financial instruments (total of 8.B.1 + 8.B.2) | Total of both in % (8.A + 8.B) | Total number of voting rights of issuer | |||
Resulting situation on the date on which threshold was crossed or reached | 11.8% | 11.8% | 128,571,514 | |||
Position of previous notification (if applicable) | ||||||
8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii | |||||||||
A: Voting rights attached to shares | |||||||||
Class/type ofshares ISIN code (if possible) | Number of voting rightsix | % of voting rights | |||||||
Direct (Art 9 of Directive 2004/109/EC) (DTR5.1) | Indirect (Art 10 of Directive 2004/109/EC) (DTR5.2.1) | Direct (Art 9 of Directive 2004/109/EC) (DTR5.1) | Indirect (Art 10 of Directive 2004/109/EC) (DTR5.2.1) | ||||||
Ordinary shares of 10p each GB00BYV3J755 | 15,176,204 | 11.8% | |||||||
SUBTOTAL 8. A | 15,176,204 | 11.8% | |||||||
| |||||||||
B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a)) | |||||||||
Type of financial instrument | Expirationdatex | Exercise/Conversion Periodxi | Number of voting rights that may be acquired if the instrument is exercised/converted. | % of voting rights | |||||
SUBTOTAL 8. B 1 | |||||||||
| |||||||||
B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b)) | |||||||||
Type of financial instrument | Expirationdatex | Exercise/Conversion Period xi | Physical or cash settlementxii | Number of voting rights | % of voting rights | ||||
SUBTOTAL 8.B.2 | |||||||||
9. Information in relation to the person subject to the notification obligation (please mark the applicable box with an "X") | ||||
Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii | ||||
Full chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entityxiv (please add additional rows as necessary) | X | |||
Namexv | % of voting rights if it equals or is higher than the notifiable threshold | % of voting rights through financial instruments if it equals or is higher than the notifiable threshold | Total of both if it equals or is higher than the notifiable threshold | |
Acacia Research Corporation | 11.8% | 11.8% | ||
Merton Acquisition Holdco LLC | 11.8% | 11.8% | ||
10. In case of proxy voting, please identify: | ||||
Name of the proxy holder | ||||
The number and % of voting rights held | ||||
The date until which the voting rights will be held | ||||
11. Additional informationxvi | ||||
Merton Acquisition Holdco LLC is a wholly-owned subsidiary of Acacia Research Corporation. | ||||
Place of completion | New York, New York, USA |
Date of completion | 28/09/2020 |
-ENDS-
For more information please contact:
Sensyne Health (www.sensynehealth.com) | +44 (0) 330 058 1845 |
Lord (Paul) Drayson PhD FREng, Chief Executive Officer | |
Michael Norris, Chief Financial Officer | |
Peel Hunt LLP (Nominated Adviser and Joint Broker) |
+ 44 (0) 20 7418 8900 |
Dr Christopher Golden | |
James Steel | |
Oliver Jackson | |
Liberum (Joint Broker) | + 44 (0) 20 3100 2000 |
Bidhi Bhoma | |
Euan Brown | |
Consilium Strategic Communications | +44 (0) 77 0286 8207 |
Mary-Jane Elliott | |
Sukaina Virji | |
Melissa Gardiner | |
CSCSensynehealth@consilium-comms.com |
About Sensyne Health
Sensyne Health plc is a clinical AI company that works in partnership with the NHS to improve patient care and accelerate the discovery and development of new medicines. Sensyne Health is listed on the AIM Market of the London Stock Exchange (SENS.L).
For more information, please visit: www.sensynehealth.com